Revises provisions governing the labeling of feminine hygiene products. (BDR 51-617)
By requiring a plain and conspicuous list of ingredients, AB169 sets a new standard for consumer product labeling. It seeks to address the growing demand among consumers for transparency, particularly concerning health-related products. The labeling requirements will include listing ingredients by their predominance by weight, which will likely influence manufacturing practices and encourage companies to prioritize safety and transparency. This bill aligns with existing laws related to the labeling of foods, drugs, devices, and cosmetics, thereby reinforcing consumer protection measures that already exist in other product categories.
Assembly Bill 169, also known as AB169, is a legislative measure introduced during the 82nd Session (2023) aimed at enhancing transparency in the labeling of feminine hygiene products. This bill mandates that all packages or boxes containing feminine hygiene products manufactured on or after January 1, 2025, must bear a conspicuous label listing all ingredients. The intent is to provide consumers with clear and accessible information about the products they are using, thus empowering them to make informed choices regarding their health and well-being.
While the primary aim of AB169 is to promote health and consumer awareness, some stakeholders may express concerns regarding the implications of enforcing stringent labeling requirements. Potential points of contention include the classification of 'confidential business information,' which allows certain ingredient details to remain undisclosed if deemed proprietary. This could be a contentious area as some manufacturers may resist full transparency to protect trade secrets. Furthermore, the bill introduces penalties for non-compliance, classified as a gross misdemeanor, raising questions about the enforcement and regulatory burden on companies, particularly smaller manufacturers.